GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Sloan Ratio %

Scancell Holdings (LSE:SCLP) Sloan Ratio % : 3.20% (As of Oct. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Scancell Holdings's Sloan Ratio for the quarter that ended in Oct. 2023 was 3.20%.

As of Oct. 2023, Scancell Holdings has a Sloan Ratio of 3.20%, indicating the company is in the safe zone and there is no funny business with accruals.


Scancell Holdings Sloan Ratio % Historical Data

The historical data trend for Scancell Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Sloan Ratio % Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.22 -8.18 -14.13 17.88 -12.81

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.72 17.88 -5.70 -12.81 3.20

Competitive Comparison of Scancell Holdings's Sloan Ratio %

For the Biotechnology subindustry, Scancell Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Sloan Ratio % falls into.



Scancell Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Scancell Holdings's Sloan Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Sloan Ratio=(Net Income (A: Apr. 2023 )-Cash Flow from Operations (A: Apr. 2023 )
-Cash Flow from Investing (A: Apr. 2023 ))/Total Assets (A: Apr. 2023 )
=(-11.936--8.14
-0.081)/30.27
=-12.81%

Scancell Holdings's Sloan Ratio for the quarter that ended in Oct. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Oct. 2023 )
=(-9.528--10.537
-0.297)/22.252
=3.20%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Scancell Holdings's Net Income for the trailing twelve months (TTM) ended in Oct. 2023 was -6.98 (Apr. 2023 ) + -2.548 (Oct. 2023 ) = £-9.53 Mil.
Scancell Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Oct. 2023 was -3.723 (Apr. 2023 ) + -6.814 (Oct. 2023 ) = £-10.54 Mil.
Scancell Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Oct. 2023 was 0.149 (Apr. 2023 ) + 0.148 (Oct. 2023 ) = £0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (LSE:SCLP) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Oct. 2023, Scancell Holdings has a Sloan Ratio of 3.20%, indicating the company is in the safe zone and there is no funny business with accruals.


Scancell Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (LSE:SCLP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines